LANTIDRA (Donislecel)

Lantidra (donislecel-jujn) is an allogeneic pancreatic islet cell therapy approved by the FDA in June 2023. It is indicated for the treatment of adults with type 1 diabetes who are unable to achieve target HbA1c due to recurrent severe hypoglycemia and who have hypoglycemia unawareness despite intensive insulin therapy. It is the first FDA-approved allogeneic islet cell product. Therapy involves one or more infusions of islet cells into the hepatic portal vein, requiring lifelong immunosuppression.